LabCorp said it will pay more than $85 million in cash for LipoScience in a bid to grow its own roster of personalized diagnostic tests. The deal, which breaks down to $5.25 per share, is yet another sign that personalized medicine is becoming more ubiquitous in the marketplace.
Here's why: The top 5 diagnostics-related venture capital deals in the 2014 second quarter are much more robust than those from the previous quarter, reflecting a larger med tech trend that produced a healthy hike in both deal value and volume versus Q1.
A year ago, Myriad Genetics launched its MyRisk Hereditary Cancer multi-gene molecular diagnostic test with great fanfare. Now, the Utah-based company is touting some eye-popping clinical trial results in a bid to reinforce its utility in the marketplace.
POPULAR COMMENT THREADS
In late 2014, the push to develop universal companion diagnostics to facilitate personal treatments for multiple cancers appears to be accelerating.
Researchers have come up with a diagnostic approach that they say could improve how autism is both identified and classified. The new technique, developed by a team at the Yeshiva University's Albert Einstein College of Medicine, joins a number of efforts with a goal of finding better ways to spot and treat the condition.
Infraredx isn't a big company yet. But the Massachusetts maker of an intravascular imaging system designed to help diagnose and manage coronary artery disease continues to meet major goals for international expansion. The latest: Japan's regulators granted approval for its signature device.
Ireland's Trinity Biotech gained a CE mark for its new heart failure point-of-care diagnostic and is now turning its sights toward the U.S. regulatory process within the next few months.
The U.K.'s Inivata raised more than $6.5 million in new financing to help advance its use of circulating tumor DNA to improve cancer testing and treatment.
T2 Biosystems, a month after launching its IPO, won FDA approval to market a new kind of test to quickly identify Candida, a bloodstream infection that can cause sepsis.
From Our Sister Sites
Philips is getting serious about consumer health, staking the entire business on merging its healthcare and consumer units into one company focused on health tech. It will spin off the lighting business into a separate company next year.
The FDA has awarded 15 grants totaling more than $19 million to spur the development of medical devices and drugs to help treat rare diseases.